ZEVRA THERAPEUTICS, INC.
Zevra Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its commercial products include MIPLYFFA, an oral treatment for neurological manifestations of Niemann-Pick disease type C in adults and children 2 years of age and older, used in combination with miglustat, and OLPRUVA, an oral suspension for certain urea cycle disorders. Zevra sells approved products through a specialty pharmacy distributor and supports commercialization with rare disease sales, marketing, market access, reimbursement, patient advocacy and medical affairs teams. Zevra is also developing celiprolol for vascular Ehlers-Danlos syndrome and KP1077 for idiopathic hypersomnia and narcolepsy. AZSTARYS, an ADHD treatment, is marketed by Commave’s affiliate Corium under an exclusive license; Zevra receives royalties and may receive milestone payments. Zevra is headquartered in Boston, Massachusetts.
Zevra Therapeutics' average price target increased from $25 to $25.25 by 8 analysts, with a range of $20 to $35. This implies a 146% upside from the Oct. 30 closing price. All 9 analysts rate the stock as Buy.
Zevra Therapeutics (ZVRA) presented at the Morgan Stanley conference, highlighting growth in its rare-disease strategy. MIPLYFFA has 184 U.S. prescriptions, 52-61% of diagnosed patients. The NPC market may be larger than initially thought. The company has $260M in cash, is debt-free, and expects EMA review clarity by Q4 2024. Celiprolol's Phase III trial is 44% enrolled but faces slower-than-expected event rates.
Zevra Therapeutics (ZVRA) will present long-term data on MIPLYFFA (arimoclomol) for Niemann-Pick disease at SSIEM 2026. Data from U.S. and German programs showed sustained stabilization and safety. MIPLYFFA was approved in September 2024. ZVRA stock closed at $11.65, up 1.29% in pre-market.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ZVRA (ZEVRA THERAPEUTICS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ZVRA coverage spans regulation, financial news and earnings.
In the last 30 days, ZVRA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($225K). The most active reporter was McFarlane Neil F., President and CEO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst target increase suggests potential upside.
The larger market estimate and strong enrollment could boost revenue outlook and support a higher valuation.
Positive long-term data may boost investor confidence and support the stock price.
This is a routine insider sale with no stated 10b5-1 plan, but it does not disclose new company fundamentals.
EU regulatory re-examination is a near-term binary catalyst for arimoclomol, with Q4 CHMP opinion timing.
AlphAI scores every news story that mentions ZVRA with an AI model for sentiment and relevance, and aggregates insider trades from ZEVRA THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Zevra Therapeutics' average price target increased from $25 to $25.25 by 8 analysts, with a range of $20 to $35. This implies a 146% upside from the Oct. 30 closing price. All 9 analysts rate the stock as Buy.
1 min readZevra Therapeutics (ZVRA) presented at the Morgan Stanley conference, highlighting growth in its rare-disease strategy. MIPLYFFA has 184 U.S. prescriptions, 52-61% of diagnosed patients. The NPC market may be larger than initially thought. The company has $260M in cash, is debt-free, and expects EMA review clarity by Q4 2024. Celiprolol's Phase III trial is 44% enrolled but faces slower-than-expected event rates.
3 min readZevra Therapeutics (ZVRA) will present long-term data on MIPLYFFA (arimoclomol) for Niemann-Pick disease at SSIEM 2026. Data from U.S. and German programs showed sustained stabilization and safety. MIPLYFFA was approved in September 2024. ZVRA stock closed at $11.65, up 1.29% in pre-market.
2 min readWatton Corey Michael sold 12,300 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $11.25 ($0.14M total) on 2026-08-10.
2 min readZevra Therapeutics (NASDAQ:ZVRA) reported Q2 updates on MIPLYFFA, including high refill, compliance and persistence, and payer coverage of 69% of covered lives. Net reimbursements were $9 million. In the EU, Zevra will re-examine arimoclomol after a CHMP negative opinion, with an expected Q4 decision. Cash was $260.2 million.
4 min readZEVRA THERAPEUTICS, INC. (ZVRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zevra Reports Second Quarter 2026 Financial Results and Corporate Update $39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2
6 min readZevra Therapeutics said the EMA CHMP issued a negative opinion on its marketing authorization application for arimoclomol to treat Niemann-Pick disease type C. Zevra plans to request a re-examination and submit supporting explanations, while continuing expanded access to generate real-world evidence. ZVRA shares closed at $9.53, down 23.92% on the day.
3 min readZevra Therapeutics (NASDAQ: ZVRA) fell after the EMA CHMP issued a negative opinion on its marketing authorization application for arimoclomol to treat Niemann-Pick disease type C. Zevra said it will request a re-examination and provide supporting explanations, and it continues expanded access to support eligible patients and gather real-world evidence.
2 min readBiotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.
7 min readZevra Therapeutics said it filed a patent for MIPLYFFA (arimoclomol) to be listed in the FDA’s Orange Book, with protection extending to 2041. The company said the Orange Book listing would strengthen MIPLYFFA’s exclusivity and could trigger an automatic stay on generic approvals if challenged. Zevra shares rose more than 9.5% on Monday.
3 min read
